BioNTech SE (BNTX) Common Equity (2018 - 2025)
BioNTech SE (BNTX) posted Common Equity of $22.4 billion for Q4 2025, up 3.6% sequentially from $21.6 billion in Q3 2025, and up 7.88% YoY from $20.7 billion in Q4 2024.
BioNTech SE (BNTX) Common Equity (2018 - 2025) Analysis & Trends
BioNTech SE has reported Common Equity for 8 years, with the latest figure at $22.4 billion in Q4 2025.
- Quarterly Common Equity rose 7.88% year-over-year to $22.4 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $22.4 billion (up 7.88% YoY) and the FY2025 annual result came in at $21.7 billion, up 4.71% from the prior year.
- Common Equity advanced to $22.4 billion in Q4 2025 per BNTX's latest filing, from $21.6 billion in the prior quarter.
- Over five years, Common Equity peaked at $22.4 billion in Q4 2025 and troughed at $3.0 billion in Q1 2021.
- A 5-year average of $18.2 billion and a median of $20.6 billion in 2024 frame the typical range for Common Equity.
- The sharpest annual moves came in 2021 and 2025: Common Equity jumped 895.88% in 2021, then retreated 8.22% in 2025.
- Over 5 years, Common Equity stood at $13.6 billion in 2021, then soared by 50.39% to $20.5 billion in 2022, then gained by 6.46% to $21.8 billion in 2023, then fell by 4.78% to $20.7 billion in 2024, then increased by 7.88% to $22.4 billion in 2025.
- According to Business Quant data, Common Equity over the past three periods registered $22.4 billion, $21.6 billion, and $20.9 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | BioNTech SE | 23.54 Bn | 5.15 Bn | 668.28 Mn | 22.38 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 22.38 Bn |
| Sep 30, 2025 | 21.60 Bn |
| Jun 30, 2025 | 20.95 Bn |
| Mar 31, 2025 | 19.91 Bn |
| Dec 31, 2024 | 20.74 Bn |
| Sep 30, 2024 | 20.99 Bn |
| Jun 30, 2024 | 20.54 Bn |
| Mar 31, 2024 | 21.69 Bn |
| Dec 31, 2023 | 21.78 Bn |
| Sep 30, 2023 | 21.63 Bn |
| Jun 30, 2023 | 21.68 Bn |
| Mar 31, 2023 | 21.75 Bn |
| Dec 31, 2022 | 20.46 Bn |
| Sep 30, 2022 | 18.52 Bn |
| Jun 30, 2022 | 17.96 Bn |
| Mar 31, 2022 | 17.86 Bn |
| Dec 31, 2021 | 13.61 Bn |
| Sep 30, 2021 | 10.27 Bn |
| Jun 30, 2021 | 6.60 Bn |
| Mar 31, 2021 | 3.04 Bn |